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The treatment of venous thromboembolic dis-
ease, whether it comprises anticoagulation therapy
alone, pharmacologic thrombolysis, or mechanical
thrombectomy, can be objectively assessed with
the quantification of the extent of thrombus at
baseline and after treatment. The Marder score
was the first such index to be described and was
originally used as a method for gauging the success
of intravenous streptokinase for deep venous
thrombosis (DVT).1 Despite the widespread use
of this measure, an objective basis for the method-
ology was not included in the original report and
the validity of the index has never been proved. An
ad hoc committee of the Society for Vascular
Surgery and the North American Chapter of the
International Society for Cardiovascular Surgery
(SVS/ISCVS) devised a simpler index for quanti-
fying venous thrombus, originally described in a
1988 publication2 and modified in a revised ver-
sion in 1995.3 The SVS/ISCVS index was devel-
oped in an attempt to standardize the reporting
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VVI was validated with the assessment of the ability to discriminate between asympto-
matic and symptomatic DVT and between those DVT that were associated with pul-
monary emboli and those that were not.
Results: With the imaging data, the VVI ranged from 1 for a single calf vein thrombus to
26 for the infrarenal inferior vena cava. Each VVI unit represented 2.3 mL of thrombus,
with a maximum possible score of 63 representing a thrombus burden of 145 mL for a
single extremity, including the infrarenal inferior vena cava. In 885 patients with DVT,
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thrombus burden, the receiver operating characteristic curve analysis results suggested
that the VVI and the Venous Registry index were better than the other two indices in the
discrimination of patients with symptomatic and asymptomatic DVT (P < .001).
Conclusion: A novel index of venous thrombus burden, on the basis of actual venous vol-
ume measurements, was more accurate than present indices in the differentiation
between clinical categories of patients with DVT. As such, it offers an acceptable alter-
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criteria of venous thromboembolic studies. Like
the Marder score, the SVS/ISCVS index repre-
sented an arbitrary method of assigning an arith-
metic score to gauge thrombus burden. Similar to
the Marder score, the SVS/ISCVS index was never
validated in a population of patients with DVT. In
response to a need for a method of quantifying
DVT before and after venous thrombolysis, a third
paradigm was developed for use with the American
Venous Registry.4 The Registry index was a modi-
fication of the SVS/ISCVS index. The index was
validated in the initial report of the Registry when
a 1-year clinical outcome was associated with the
change in the index after urokinase thrombolysis.
Despite this finding, the Registry index was not
based on a quantitative estimate of thrombus
mass—an important attribute of a valid index of
venous thrombus. Further, calf vein thrombi were
not included in the methodology, which account-
ed for an underestimation of the extent of the
thrombotic process in many patients.
Because of the perceived shortcomings of the
existing indices to gauge the extent of venous throm-
bosis, a new method was developed on the basis of
actual volumetric calculations made from imaging
studies of patients with DVT. This new index was val-
idated through an assessment of its ability to discrim-
inate patients with symptomatic versus asymptomatic
DVT and patients with pulmonary embolism versus
patients without.
METHODS
The pelvic venous measurements were made from
computerized tomographic imaging study results
from 13 patients, with the tabulation of the diameters
of the external iliac, hypogastric, and common iliac
veins and of the infrarenal inferior vena cava. Pelvic
venographic results were evaluated in a separate group
of 10 patients to calculate the length of the same
venous segments. The infrainguinal venous measure-
ments were obtained from the results of duplex ultra-
sound scans (diameter determinations) that were per-
formed in 12 patients and from the results of
venograms (length determinations) that were per-
formed in 10 patients. The common femoral, profun-
da femoris, superficial femoral, popliteal, and calf vein
segments were evaluated. The volume of each seg-
ment was calculated as the product of p , length, and
the square of the radius. In this manner, an estimate
of the actual volume of venous thrombus was assigned
to each of four abdominopelvic venous and 10 lower
extremity segments. A point value was assigned to
each of the segments with the normalization of the
volume of each segment to the volume of a calf vein
and the rounding to the nearest integer, such that the
score for a single calf vein was 1. For technical rea-
sons, the soleal and gastrocnemius veins were exclud-
ed from the methodology. These segments were
inconsistently visualized on the imaging study results.
A venous volumetric index (VVI) was calculat-
ed for each patient with the summation of the rep-
resentative scores for each thrombus-containing
venous segment. The partially occlusive thrombi
were assigned a score equal to one half of the point
value for that particular segment. The VVI was not
corrected for the thrombotic involvement of one of
two paired proximal veins (eg, double popliteal or
duplicated superficial femoral veins), but the index
did account for the involvement of one versus both
paired calf veins.
During a l0-year period, a total of 2534 lower
extremity venographic procedures were performed
and were of sufficient quality for review. Of these,
885 cases (34.9%) had evidence of acute DVT, and
this subset of all positive venographic results repre-
sented the clinical database used to validate the VVI.
Validation was accomplished through an assessment
of the index in the subgroups of patients with
asymptomatic versus symptomatic DVT and in those
patients with DVT and pulmonary embolism docu-
mented with radionuclide scanning, pulmonary
angiography, or dynamic computed tomography.
Similar statistical calculations were made for the
Marder score and the SVS/ISCVS and Registry
indices. The comparative validity of the different
indices of thrombus burden were compared with the
determination of the ability of each measure to dif-
ferentiate between the following three clinical cate-
gories: patients who were asymptomatic, patients
who were symptomatic, and patients with pul-
monary embolism. In this manner, the most valid
index would be associated with the greatest degree
of discrimination between these categories, assessed
through receiver operating characteristic (ROC)
curve analysis. ROC curves were generated for each
index and graphed the relationship between the
true-positive rate and the false-positive rate. The
performance of each index was displayed as it relat-
ed to the discrimination between: (1) those patients
who were asymptomatic versus those patients who
were symptomatic, and (2) those patients with pul-
monary emboli versus those patients without. A P
value was generated for the comparisions between
the two ROC curves with the method of Metz.5
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RESULTS
Calculation of the venous volumetric index
scores by anatomic segment. With the measure-
ments from the computed tomographic images,
venograms, and duplex scans, the volumetric scores
for the various venous segments ranged from 1 for a
single calf vein to 26 for the infrarenal inferior vena
cava (Table I) and corresponded to a ratio of 2.30
mL of thrombus per unit VVI. The maximum possi-
ble VVI was 63 for one leg, which represented the
sum of the scores for all nine segments. With the
conversion factor of 2.30 mL/U, there was a maxi-
mum thrombus burden of 145 mL within the deep
venous segments of one leg, including the infrarenal
inferior vena cava, and 85 mL exclusive of the cava.
When grouped by anatomic system, the calf veins
accounted for 16% of the total (excluding caval)
thrombus burden of each leg, verus 43% for the
femoropopliteal system and 41% for the iliac system
(Table II).
Venous volumetric index determinations in
patients with deep venous thrombosis and pul-
monary embolism. The VVI ranged from 1 to 56
in the 885 patients with DVT. The VVI was signifi-
cantly lower in the patients with asymptomatic ver-
sus symptomatic DVT (3.9 ± 0.2 vs 8.7 ± 0.3,
respectively; P < .001; Table III). An apparently
lower mean VVI in the patients without clinically
significant pulmonary emboli was not statistically
different from the VVI in patients with such a histo-
ry (7.7 ± 0.2 vs 9.6 ± 1.2, respectively; Table IV).
Although the patients with pulmonary emboli had a
mean residual lower extremity thrombus burden of
21 ± 0.5 mL, pulmonary emboli were observed in
patients with as little as a 6-mL residual thrombus.
Comparison of different indices of thrombus
burden. The comparative validity of the four indices
of thrombus burden was assessed with the tabulation
of the number of asymptomatic patients whose scores
were above the threshold (95% confidence interval for
the symptomatic group) and of the number of symp-
tomatic patients whose scores were beneath the
threshold (95% confidence interval for the asympto-
matic group). The VVI and the Registry index
appeared to be the most valid measures, with the low-
est rates of improperly categorized patients (Table V).
There was a trade-off between the false identification
of asymptomatic versus symptomatic patients, howev-
er. The Registry index was best for the correct identi-
fication of patients with asymptomatic DVT, and the
SVS/ISCVS index was best for the discrimination of
patients with symptomatic DVT.
With ROC curve analysis (Fig 1), the VVI and
the Registry index offered improved discrimination
between asymptomatic and symptomatic DVT when
compared with either the Marder score (P < .001, vs
VVI; P < .001, vs the Registry index) or the
SVS/ISCVS index (P < .001, vs VVI; P < .001, vs
the Registry index). There were no statistically sig-
nificant differences noted between the discriminato-
ry value of the VVI versus the Registry index (P =
.838) or of the Marder score versus the SVS/ISCVS
indices (P = .863). When the indices were evaluated
with respect to the discrimination of those thrombi
that were associated with pulmonary emboli versus
those that were not, the VVI and the Registry index
also appeared better than the other two measures,
but the small numbers of patients with pulmonary
emboli precluded a meaningful statistical analysis.
DISCUSSION
The advent of therapies directed at clearing
thrombi from the venous system has appropriately
prompted the performance of trials designed to
assess the benefits of such treatments in an objective
fashion.6-10 The availability of a valid index with
which to gauge the extent of DVT is crucial to the
conduct of these investigations, both to assess the
success of thrombolytic and other treatment meth-
ods and to compare the baseline status of different
groups of patients.
At least three scoring systems for venous throm-
Table I. Methodology used to calculate the
venous volumetric index
Length Diameter Volume
Segment (cm) (cm) (mL) Ratio Score
Inferior vena cava 14.0 2.34 60.21 26.22 26
Common iliac 6.0 1.39 9.10 3.97 4
Hypogastric 7.0 0.91 4.55 1.98 2
External iliac 13.0 1.40 20.01 8.72 9
Common femoral 6.0 1.41 9.37 4.08 4
Superficial femoral 20.0 0.96 14.60 6.36 6
Profunda femoral 12.0 0.85 6.81 2.97 3
Popliteal 15.0 0.82 7.86 3.42 3
Each calf vein 18.0 0.40 2.30 1.00 1
Table II. Volume and relative contribution by
anatomic system
Region Volume (mL) Percent
Iliac 32.1 41
Femoropopliteal 34.2 43
Calf 12.8 16
Total 79.18 100
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Fig 1. Receiver operating characteristic curves for differentiation of asymptomatic and symp-
tomatic deep venous thrombosis. Numbers along lines indicate criterion thresholds points
along receiver operating characteristic curves.
Table III. The venous volumetric index in symptomatic and asymptomatic deep venous thrombosis, con-
trasted with the Marder score, the Society for Vascular Surgery/North American Chapter of the
International Society for Cardiovascular Surgery index, and the Registry index
VVI Marder score SVS/ISCVS Registry
Asymptomatic DVT
No. of patients 169 169 169 169
Mean 3.9 9.4 2.3 0.5
SD 2.7 5.7 1.9 1.0
SEM 0.2 0.4 0.1 0.1
95% CI 3.5 - 4.3 8.5 - 10.3 2.0 - 2.6 0.3 - 0.6
Median 2.0 6.0 1.0 0.0
Range 1.0 - 13.0 2.0 - 24.0 0.5 - 9.0 0.0 - 4.0
1st quartile 2.0 6.0 1.0 0.0
3rd quartile 6.0 16.0 3.0 0.0
Symptomatic DVT
No. of patients 716 716 716 716
Mean 8.7 14.2 5.0 2.4
SD 7.6 8.0 3.5 2.5
SEM 0.3 0.3 0.1 0.1
95% CI 8.1 - 9.3 13.6 - 14.8 4.8 - 5.3 2.2 - 2.6
Median 6.0 14.0 4.0 2.0
Range 1.0 - 56.0 0.0 - 34.0 0.5 - 17.0 0.0 - 12.0
1st quartile 4.0 6.0 2.0 0.0
3rd quartile 13.0 20.0 8.0 4.0
VVI, Venous volumetric index; SVS/ISCVS, Society for Vascular Surgery and the North American Chapter of the International Society
for Cardiovascular Surgery; DVT, deep venous thrombosis; SEM, standard error of the mean; CI, confidence interval.
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bosis have been used. The first of these to be
described, the Marder score, is the only index that
was based on the volume of venous thrombus with-
in each anatomic segment.1 The Marder score is,
however, somewhat arbitrary. The data on which the
scores were based did not appear in the publication,
although each score was said to reflect the calculat-
ed volume of the corresponding segment. The
Marder score also failed to separate the relative con-
tributions of thrombus within the three iliac veins,
and the contributions of the profunda femoral vein
and the inferior vena cava were excluded from the
scoring system. Calf DVT appears to be over repre-
sented in the Marder score, accounting for fully 40%
of the total lower extremity score and an amount
greater than that assigned to either of the more
proximal femoropopliteal or iliac regions.
The SVS/ISCVS3 and Registry indices4 are not,
per se, based on the volume of thrombus. These
methods assign arbitrary values to each of the venous
segments. Whereas the SVS/ISCVS methodology
includes scores for the soleal and gastrocnemius veins,
the Registry index ignores thrombus below the
popliteal level. Despite the arbitrary nature of these
measures, they are remarkable in their ability to dis-
criminate asymptomatic and symptomatic DVT.
Although the Registry index performed well in the
present analysis, the failure to include calf vein throm-
bi makes it less useful for the quantification of the
total thrombus burden in patients with DVT.
The VVI appears to offer an acceptable alterna-
tive to the current scoring methods. Unlike other
methods, it is strictly based on venous volume mea-
surements and therefore provides a more accurate
assessment of thrombus mass. Normalization to the
volume of a single calf vein and rounding to the
nearest integer makes the VVI easy to use. It better
discriminated symptomatic from asymptomatic
thrombi when compared with both the Marder
score and the SVS/ISCVS index and was as accurate
Table IV. The venous volumetric index in patients with and without clinically significant pulmonary
emboli, contrasted with the Marder score, the Society for Vascular Surgery/North American Chapter of
the International Society for Cardiovascular Surgery index, and the Registry index
VVI Marder SVS/ISCVS Registry
No PE
No. of patients 853 853 853 853
Mean 7.7 13.1 4.4 2.0
SD 7.2 7.9 3.4 2.4
SE 0.2 0.3 0.1 0.1
Confidence 0.5 0.5 0.2 0.2
95% CI 7.2 - 8.2 12.6 - 13.7 4.2 - 4.7 1.8 - 2.2
Median 6.0 12.0 3.0 2.0
Range 1.0 - 56.0 0.0 - 34.0 0.5 - 17.0 0.0 - 12.0
1st quartile 2.0 6.0 1.0 0.0
3rd quartile 11.0 20.0 7.0 4.0
PE
No. of patients 32 32 32 32
Mean 9.6 17.1 5.9 2.7
SD 6.9 7.4 3.2 2.7
SEM 1.2 1.3 0.6 0.5
Confidence 2.4 2.6 1.1 0.9
95% CI 7.2 - 12.0 14.6 - 19.7 4.8 - 7.0 1.8 - 3.6
Median 8.0 17.0 5.8 2.0
Range 3.0 - 30.0 4.0 - 34.0 2.0 - 14.0 0.0 - 10.0
1st quartile 6.0 12.0 3.0 1.8
VVI, Venous volumetric index; SVS/ISCVS, Society for Vascular Surgery and the North American Chapter of the International Society
for Cardiovascular Surgery; PE, pulmonary embolism; SEM, standard error of the mean; CI, confidence interval.
Table V. Discriminatory abilities of the indices
VVI Marder SVS/ISCVS Registry
1. Asymptomatic, 9.5% 28.4% 13.0% 4.7%
> threshold*
2. Symptomatic, 34.1% 40.9% 26.8% 36.2%
< threshold†
VVI, Venous volumetric index; SVS/ISCVS, Society for Vascular
Surgery and the North American Chapter of the International
Society for Cardiovascular Surgery. 1. Percentage of asympto-
matic patients with index incorrectly more than threshold. 
2. Percentage of symptomatic patients with index incorrectly less
than threshold.
*Threshold defined by the lower limit of the 95% confidence
interval for the symptomatic patients.
†Threshold defined by the upper limit of the 95% confidence
interval for the asymptomatic patients.
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as the Registry index in this regard. The inclusion of
calf vein thrombi in the VVI scoring methodology
may render this index more attractive than the
Registry index. For these reasons, the VVI appears
to be a useful scoring paradigm for the assessment of
venous thrombus burden and of the changes in
thrombus after intervention. Nevertheless, the valid-
ity of the index remains to be proven with regard to
its association with the long-term sequelae of DVT.
A valid index would be one that would be closely
linked to post-thrombotic complications. This fea-
ture can only be assessed with the comparison of the
VVI to other scoring systems in longitudinal studies
of patients with DVT, a feature that must be criti-
cally assessed before the VVI can replace the avail-
able indices as the methodology of choice in venous
thromboembolic studies.
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Dr Enrico Ascher (Brooklyn, NY). I would like to
start by thanking the Program Committee for asking me
to discuss this interesting and well-presented paper. I con-
sider this both a duty and an honor.
It is not unexpected that Dr Ouriel, Dr Greenberg,
and colleagues have attempted to develop new indices to
better assess the results of venous thrombolysis. Their con-
tributions to this field of vascular intervention have been
recognized by the most stringent editorial boards.
Approximately 23 years ago, Victor Marder and his
associates at Temple University developed a quantitative
venographic assessment of acute deep vein thrombosis
whereby a scoring system was developed according to the
location and extent of the thrombotic process. With this
scoring system, they prospectively demonstrated in
patients that the rate of clot resolution was significantly
higher for streptokinase when compared with heparin.
Today Dr Greenberg has introduced a more refined
method in which not only the site and the extent of the
clot are taken into consideration but also the volume.
Clearly, the new scoring system is less arbitrary than the
one described by Marder. Of course, if volume of clot
were the only criterion for the prediction of success or fail-
ure of any treatment protocol, I would congratulate Drs
Greenberg and Ouriel, pack, and go home.
However, deep vein thrombosis is a dynamic process
that is constantly changing and that is subject to a myriad
of processes related to thrombogenic and thrombolytic
stimuli. Even anatomically, the response to exogenous
thrombolytic agents may vary according to the length or
diameter of the vein and not necessarily the volume. It
seems logical to me that six completely occluded
infrapopliteal veins would take longer to lyse than one
external iliac vein segment. Yet, the venous volumetric
index for the latter is much higher than for the
infrapopliteal veins: 9 versus only 6. Dr Greenberg, could
you please comment on this assumption?
Also, I wonder why you used a different number of
patients when you calculated the length and diameter of
the vein segments? Was there any attempt made to include
the superficial venous system into this scoring? This may
potentially influence the long-term results of venous insuf-
ficiency and its sequelae.
In the same breath that the authors are proposing the
preferential use of venous volumetric index scoring, they
conclude that the Registry index was best at correctly
identifying patients with asymptomatic deep venous
thrombosis and that the index of the Society for Vascular
Surgery and the North American Chapter of the
International Society for Cardiovascular Surgery was best
at discriminating those patients with symptomatic deep
venous thrombosis. Of course, in my practice, if I want to
find out about symptoms, I simply ask the patient.
Furthermore, none of the indices presented today reli-
ably predicted pulmonary embolism. In our experience,
the best criterion has been the demonstration of clot
DISCUSSION
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extension despite adequate systemic anticoagulation ther-
apy. Could you comment on the potential benefits of
repeat venous volumetric index scores?
Also, did you by any chance divide the 885 patients
with proven deep venous thrombosis into those patients
with suprainguinal extension versus those patients with
deep venous thrombosis limited to the infrainguinal loca-
tion? How would the venous volumetric index fare as a
predictor of pulmonary embolism in both groups? You
may have been surprised to find that perhaps the proximal
extension has a higher rate of pulmonary embolism.
As the authors correctly pointed out on their well-
written manuscript, longitudinal studies of patients with
deep venous thrombosis are critical to validate the pro-
posed scoring system. In the meanwhile, I want to con-
gratulate Dr Ouriel, Dr Greenberg, and colleagues for
their continued efforts to improve on standard method-
ologies. Perhaps they should consider a multi-institution-
al project to definitively validate the venous volumetric
index scoring system.
Once again, I would like to thank the Society for this
assignment and the authors for allowing me to review
their well-organized manuscript. Thank you.
Dr Roy K. Greenberg. Thank you, Dr Ascher, for
your comments and eloquent discussion.
With respect to your first question about the calcula-
tion of calf vein thrombosis versus a single external iliac
thrombosis, our scoring system is really not designed to
assess the time it takes to complete lysis or the success of
lysis. What we really want to do is determine, prospective-
ly, whether or not these patients are going to get better,
become symptomatic, or benefit from lysis. Perhaps, if a
patient had a high score and we were able to lower that
score with lysis, we may improve their symptoms.
Because this is a comprehensive index designed to
assess all lower extremity deep venous thrombosis, there
will be unusual situations in which the scores may not
accurately reflect the clinical scenario. If this were not the
case, we would be 100% sensitive and specific.
We consciously elected not to include the superficial
venous system in the venous volumetric index because we
are not aware of any studies that define its relationship to
the deep venous system in the setting of deep venous
thrombosis. To include that within the venous volumetric
index would require a great deal of speculation. We have
to remember that the purpose of this is to evaluate the
need of benefit of treatment for venous thrombosis.
The system is designed to allow clinicians to obtain
sequential scores. The first score is assessed before any treat-
ment, and the second score is assessed at each follow-up
venographic evaluation during the treatment. We are look-
ing for a change in the score and trying to correlate that
with a change in the symptoms or the presence of reflux.
We did not segregate the patients into those with
infrainguinal or suprainguinal disease by looking for clini-
cal sequelae on the basis of those anatomic discrepancies.
That may be something that is worthwhile in the future.
I think that addressed your questions.
Dr Herbert Dardik (Englewood, NJ). This sounds
labor intensive to me. How long does it take to do a cal-
culation per patient?
Dr Greenberg. Well, it is actually quite simple once you
are familiar with it. But you are right, it is somewhat labor
intensive. However, venous thrombosis is not a simple prob-
lem. We have been thwarted for many years when attempt-
ing to develop longitudinal studies that compare patients. A
complex scoring system may be a price we have to pay.
Dr Peter J. Pappas (Newark, NJ). That was a great
presentation. I have always been intrigued by the concept
of the amount of clot in a vein and whether or not we
could somehow use that to predict a successful throm-
bolytic event. As a matter of fact, at the American Venous
Forum meeting, when Dr Mewissen presented the data
from the registry before it was published, I was intrigued
by the fact that the iliac segments had a higher rate of
thrombolysis and success and that the femoropopliteal
segments had an abysmal response. I have always won-
dered why this is so. Recently, I spoke with Tom Wakefield
and I saw some of his data on vein wall inflammation. I
wondered whether there was a differential response in vein
wall inflammation in the femoropopliteal segment as
opposed to the iliac segment.
I bring this up because I have always been intrigued by
Dr Nicolaides’ plaque morphology work, and I wonder
why we cannot translate that into the deep venous system
to do some kind of clot morphology work or maybe vein
wall morphology work. It seems to me that the system
that you have used with your computed tomographic
scanning and your duplex scanning might be able to be
applied in that way. So, I wonder whether you intend to
do any of that clot morphology or vein morphology work
and whether or not it may help you determine a success-
ful thrombolytic event.
Dr Greenberg. I completely agree with you, especially
with your comments about the femoropopliteal segment.
Given the frequency of thrombosis of this segment, it is
the most underserved, primarily because we have not been
able to document good results with treatment. Perhaps
that is because of the clot morphology, perhaps it is
because of the number of valves or the fibrotic nature of
the valves or vessel wall, or perhaps it is a different biolog-
ic entity than iliac vein thrombosis. One of the concerning
things that comes to mind is that most patients with iliac
clot also have femoral clot and frequently popliteal clot.
These patients are a difficult population to treat, and they
are the patients who have the highest scores in these
indices and probably the worst prognoses in terms of
long-term consequences. Any further definition in this
area would be beneficial. However, we have not embarked
on this pathway yet.
